News from the life sciences community north of Boston
March 2022
With spring nearly here, we are delighted to return to in-person events. North Shore Technology Council invites the life sciences community to Cummings Center, Beverly, for a Fireside Chat with the MassBio Leadership Team on Tuesday, March 29, at noon. This Biosciences Forum will feature a conversation between NSTC president Tracy Curley, recently appointed MassBio CEO Joe Boncore, and MassBio president Kendalle Burlin O'Connell.
The program will be held in the Community Conference Room at 100 Cummings Center, Suite 221-E, and lunch will be served. Space is limited at this free event, so please register.
As the invasion of Ukraine continues, two pharma industry leaders are stepping up actions against Russia, reports Endpoints News. Yesterday, Pfizer and Bayer announced steps to limit business dealings in Russia. Pfizer will no longer initiate new clinical trials in Russia, and will curb manufacturing capacity by ceasing all planned investments with local suppliers. Bayer will stop all spending in Russia and Belarus not related to supplying essential products in health and agriculture.
Cambridge-based Korro Bio recently closed a $116 million financing round and looks forward to advancing its R&D pipeline in a new 18,350 SF lab and office space at Cummings Park, in Woburn.

Korro Bio is an RNA editing company focused on discovering and developing precision genetic medicines to treat a wide range of rare and prevalent diseases. Korro combines data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing through a safe and cost-effective drug product.

Members of Korro Bio's leadership team include (l to r): Ram Aiyar, CEO and president; Vineet Agarwal, chief financial officer; Todd Chappell, SVP strategy and portfolio planning; Anna Barry, chief operating officer; Howard Stern, chief scientific officer; and Andrew Fraley, co-founder and chief technology officer.
CEO Shelley Hartman (r) and Tom Schulz of Aegle Therapeutics recently toured the company's newly completed Emerging Tech Center lab space at 48 Dunham Ridge, Beverly.

´╗┐This first-in-class, phase 1/2a biotechnology company is isolating extracellular vesicles from allogenic bone marrow-derived mesenchymal stem cells to treat severe dermatological conditions.
QIAGEN (100 Cummings Center, Beverly) is expanding its 46,000 SF operations with the addition of a new 2,000 SF lab. The auxilliary lab space will serve as QIAGEN's local eight-person Quality Control team, led by Catherine Conti.

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life.
In June 2021, Adept Therapeutics was the first company to open a lab at the Dunham Ridge Emerging Tech Center. The company is quickly growing, and recently expanded with 764 additional square feet of lab and office space.

Led by co-founder, president, and CEO Xinyan (Cindy) Zhao, Adept is working to discover and develop potentially life-changing medicines for people with unmet medical needs. The company leverages multiple advanced antibody technologies to discover fully human or humanized antibody therapeutics to enhance anti-tumor immunity.
Congratulations to North Shore InnoVentures (NSIV) (100 Cummings Center, Beverly), which will receive $3.1 million in capital funds as part of the Massachusetts Life Sciences Center Research Infrastructure program. NSIV is one of ten projects to receive a total of $28.3 million through the program. Matching funds committed by the recipient institutions and their partners make a combined total of more than $50 million.
"These strategic investments will help Massachusetts maintain its position as a global leader in life sciences innovation. Our Administration is proud of its continued commitment to providing essential funding that supports this pivotal sector of our economy, while also advancing critical research and scientific development."

- Governor Charlie Baker
New NSIV member BioLumic is among the latest companies to join the robust life sciences community in Boston's MetroNorth. The company's UV technology delivers ultra-violet light to seeds and seedlings to trigger biological mechanisms that increase plant growth, vigor, and yields.
Team members Scott Schaeffer, R&D lead, and Christine Conner, agronomist III, are seen here at NSIV.
NSIV also welcomes TurtleTree, a company that uses modern cell-based technology to create sustainable food products that are better for the planet, animals, and human consumption.

The Singapore start-up expects to launch its first products through multiple B2B partnerships in the U.S. soon. TurtleTree plans to fully commercialize its cultured milk, made using its cell-based dairy ingredients, within the next four to five years.
Axial Therapeutics (400 TradeCenter, Woburn) is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions. The company's CEO, A. Stewart Campbell, Ph.D., recently discussed the gut-brain axis in neurodevelopment disorders like autism in an interview with Bloomberg Radio. (Tune in at 21:18).
Axial also announced the publication of full results from its phase 1b/2a clinical trial of AB-2004 in Nature Medicine. AB-2004 is being studied as a potential new treatment for managing irritability associated with Autism Spectrum Disorder (ASD) in children and is the company's lead gut-targeted molecular therapeutic.
Nth Cycle (100 Cummings Center, Woburn) has announced the closing of its $12.5 million Series A financing, co-led by the investment arm of Frankstahl and Volo Earth. The innovative metal processing and recycling technology company is disrupting the critical mineral supply chain necessary for electric vehicles, solar power, and energy storage through a groundbreaking recycling, mining, and refining process. Learn more about the news in this video.
Vaxess Technologies is expanding its GMP manufacturing facilities at Cummings Park, in Woburn, and now occupies a second new facility in Cambridge. The new headquarters will house the company's administrative and R&D teams.

Vaxess has also bolstered its management team with the addition of part-time CFO Peter Courossi, and VP of Device Development John Spiridigliozzi.
Lab Opportunity in Woburn
Coming available September 2022: a 3,600 SF laboratory and vivarium suite at 175 New Boston Street, Woburn. Contact or 781-935-8000 for more information. Features:
  • Vivarium with procedure and holding rooms
  • Includes epoxy flooring and dedicated HVAC system with pressure controls
  • 100 kW generator
  • Metal casework, resin countertops, plastic laminate reagent shelves
  • Private loading dock
  • 6' chemical fume hood with airflow alarm
  • Lab plumbing system has floor drains, utility sinks, and Ph adjustment tanks
  • Process piping and gas manifold
  • RO/DI water system
  • 100% outside air in lab areas
  • DriSteem humidifier
175-E New Boston Street, Woburn - 3,600 SF
MassBio St. Patrick's Day Mixer: Join MassBio for a members-only mixer at MassBioHub in Cambridge. Appetizers and drinks will be served. Thursday, March 17, at 5:00 PM. Register.
In-person Biosciences Forum: Fireside Chat with Dr. Ed Kay, CEO of Stoke Therapeutics moderated by Tracy Curley, president and CFO of iSpecimen. Thursday, April 28, at 5:00 PM at TradeCenter 128 in Woburn.

Dr. Kaye will share his experiences as an executive in the biotech industry as it faces innovation, commercialization, and financial opportunities and challenges. Learn about Dr. Kaye's leadership journey through this critical and everchanging industry. $25 for members and $35 for non-members. Register.
Dr. Paul Farmer with Joyce and Bill Cummings, co-founders of Cummings Foundation
The untimely passing of Dr. Paul Farmer has been mourned around the world - as the impact of his bold, tireless advocacy for health care access was truly global. It has been a real privilege for all at Cummings Foundation to collaborate with such a visionary leader, who has touched, improved, and literally saved countless lives. We are grateful to Paul and deeply appreciate that his vision will continue on through the work of many dedicated colleagues at University of Global Health Equity in Rwanda and Partners In Health.
Keep up with news from the Cummings community by following us on LinkedInFacebookTwitter, and Instagram.